About Emmaus Life SciencesEmmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. IndicationEndari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established. About Sickle Cell DiseaseThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. 2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

Source: The North Africa Journal March 31, 2026 02:09 UTC